STRATEGY

Diverse Pipeline

Because Appili is not bound to a single technology, platform, or therapeutic indication, we can evaluate a broad range of opportunities aligned with national security healthcare priorities. We focus on solutions that address critical needs across defense, government, and commercial healthcare markets, creating multiple potential pathways for growth and long-term value creation

Appili Therapeutics was founded to acquire, develop, and commercialize novel therapeutics addressing biodefense and infectious disease priorities. Today, we are expanding that foundation into a broader National Security Healthcare company focused on technologies that protect military personnel, strengthen national resilience, and address high-priority healthcare needs. This evolution positions Appili at the intersection of healthcare innovation, government priorities, and growing demand for medical preparedness and protection.

Our defense and health-security portfolio is designed to identify and advance solutions addressing high-priority national security and healthcare needs. We seek opportunities across biodefense, physiological readiness, diagnostics, biosurveillance, infectious disease and protection against chemical, biological, radiological, and nuclear threats. 

A key focus is dual-use innovation—including therapeutics, diagnostics, medical devices, and manufacturing capabilities—with potential applications across defense, government, and commercial healthcare markets. This approach allows Appili to pursue opportunities with multiple potential development, funding, procurement, and commercialization pathways. 

 

A Platform Build for Complex Healthcare Challenges

Appili brings together regulatory and drug development with partnership experience to advance medical technologies for biodefence and national security healthcare

Military Picture 2
01

Emergency Use Authorization

Experience navigating emergency use authorization frameworks and pre-EUA development pathways to support expedited regulatory strategies.

02

Priority Review Voucher Opportunities

Drug development and regulatory expertise involving neglected tropical diseases and rare pediatric indications with potential PRV value.

03

Government Partnerships

Experience working with government funding programs, procurement agencies and strategic research partners.

04

Stockpile & Procurement Readiness

Understanding military and homeland security requirements, medical countermeasure needs and stockpiling considerations.

Seeking additional programs that align with our balance risk portfolio strategy:

Near to market/revenue or
commercial opportunities

Transformational programs to
tackle the most serious threats

An important aspect of this approach to portfolio-building is discipline – Appili’s team has reviewed and passed on more than 150 drug development projects that did not meet our rigorous scientific, clinical, patient-care, and strategic corporate criteria. The inherent flexibility in our approach also allows us to pursue opportunities that provide access to non-dilutive funding from government incentive programs or industry partnerships.

The Budget

Dual-Use Military & Civilian Technology

A shared technology opportunity across defense preparedness and civilian healthcare markets.

$839 Billion

Announced Funding

from the U.S.

Department of War

$1.2 Trillion

2025 Medicare

benefit payments 

$1.6 Trillion

2025 total hospital

expenditures

Dual Use

Two markets. One opportunity

Explore the applications of dual-use technologies across military readines and civilian healthcare

Military & Preparedness

Develop medical countermeasures to protect deployed personnel and pursue government procurement for defined readiness needs

Civilian Procurement

Develop medicines for patients and work with commercial or global health partners to make them available

Government/military non-dilutive funding

Fund Appili for validation, advance technology without diluting shareholders

Government procurement

Successful technology earn Appili procurement revenue or stockpile contracts, even before commercial launch

Civilian market commercialization

Appili can then commercialize the same technology in the private sector / civilian applications